Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis
暂无分享,去创建一个
K. Yamashita | W. Koizumi | H. Moriya | N. Katada | C. Katada | K. Hosoda | H. Mieno | K. Hoshi | M. Watanabe